This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

tocilizumab (RoActemra®)

Reference No. 2662

Publication date:

Appraisal information

tocilizumab (RoActemra®) 162 mg subcutaneous injection

Company: Roche Products Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: 2662
Ratification by Welsh Government: 05/03/2019

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, tocilizumab (RoActemra®) cannot be endorsed for use within NHS Wales for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 years to < 2 years of age, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to methotrexate [MTX] or where treatment with MTX is inappropriate) or in combination with MTX
Statement of Advice (SOA)